[Federal Register Volume 78, Number 245 (Friday, December 20, 2013)] [Notices] [Page 77107] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2013-30367] ----------------------------------------------------------------------- DEPARTMENT OF DEFENSE Department of the Army Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Antibody- Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies AGENCY: Department of the Army, DoD. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/762,543, entitled ``Antibody-Dependent Cellular Cytoxicity (ADCC)- Mediating Antibodies,'' filed on February 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619- 6664, both at telefax (301) 619-5034. SUPPLEMENTARY INFORMATION: The invention relates to Antibody-Dependent cellular cytoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2013-30367 Filed 12-19-13; 8:45 am] BILLING CODE 3710-08-P